From: Is pathology necessary to predict mortality among men with prostate-cancer?
 | HR 95% CI | p | |
---|---|---|---|
Age | 1.084 (1.06-1.106) | <0.0001 | |
Year of cohort entry | 0.806 (0.78-0.83) | <0.0001 | |
Rural | 1.31 (0.99-1.74) | 0.054 | |
Co morbidity ADGs | Low | Ref | Â |
Intermediate | 1.33 (1.004-1.77) | 0.047 | |
High | 1.49 (1.1-1.97) | 0.0043 | |
SES status | 1 | Ref | Â |
2 | 0.846 (0.60-1.18) | 0.32 | |
3 | 1.2 (0.87-1.68) | 0.26 | |
4 | 0.85 (0.59-1.21) | 0.36 | |
5 | 0.88 (0.63-1.25) | 0.49 | |
Gleason grade | Low | Ref | Â |
Intermediate | 1.66 (1.14-2.4) | 0.0076 | |
High | 5.97 (4.2-8.47) | <0.0001 | |
Volume of prostate cancer | Low (≤30%) | Ref |  |
High ( >30%) | 1.62 (1.23-2.33) | 0.0012 |